

Saliva based diagnostics of Pancreatic cancer (Yissum)

code: 7-2010-2528

[Aaron Palmon](#), HUJI, Faculty of Dental Medicine, Institute of dental sciences

Categories	Diagnostics, Oncology/Cancer, Peptide/Protein
Development Stage	Early development
Patent Status	Provisional patent filed in the United States
Market	<p>In the United States, pancreatic cancer is the fourth leading cause of cancer-related death in both men and women with an estimated over 43,000 new cases and over 37,000 deaths from pancreatic cancer in 2012:</p> <p>Overall pancreatic cancer incidence and mortality rates have changed very little throughout the past three decades.</p>

Highlights

- Pancreatic cancer is usually diagnosed at an advanced stage and the survival rate is poor compared with those for other cancer types.
- Several biomarkers identified in saliva samples of pancreatic cancer patients may serve as accurate predictors of the disease
- Survival from pancreatic cancer has not been improved substantially during the past 30 years, mainly due to difficulties in early diagnosis. Nowadays, early detection of pancreatic cancer for patients at high-risk is done by invasive means (endoscopic ultrasound combined with fine-needle-aspiration).
- Preparing to develop flow stick to indicate biomarkers for pancreatic cancer in saliva.
- The group specializes in salivary research including salivary biomarkers discovery and saliva based lateral flow immunoassays (LFIS) development.
- An array of salivary biomarkers (proteins) that had been identified from saliva of pancreatic cancer patients.

Our Innovation

- Efficient method for detecting biomarkers for pancreatic cancer in saliva

Key Features

- Simple, non-invasive test.
- Wide screening potential
- Early detection enables more effective treatment
- Low-cost
- May be applied and developed for other diseases

Development Milestones

- Seeking funding for ongoing research to identify the correct markers for the disease

The Opportunity

- Since symptoms in pancreatic cancer usually appear too late to enable effective treatment, saliva screening for the disease will need to be included as one of the tests in routine health checks.

Contact for more information:

Ariela Markel , VP, Business Development, Healthcare, +972-2-6586608

Yissum Research Development Company of the Hebrew University of Jerusalem
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390
Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689